⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30867766 | 1.00 | — | — | |
| SCHEMBL11985905 | 0.79 | — | — | |
| SCHEMBL9797875 | 0.79 | — | — | |
| SCHEMBL15006461 | 0.75 | — | — | |
| SCHEMBL27803144 | 0.75 | — | — | |
| SCHEMBL384814 | 0.72 | — | — | |
| SCHEMBL30124861 | 0.72 | — | — | |
| SCHEMBL27749982 | 0.72 | NOS3 (0.31) | — | |
| SCHEMBL31326195 | 0.70 | KDM4E (0.32) | — | |
| SCHEMBL30867941 | 0.69 | PDE10A (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4598917-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| WO-2024076674-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| EP-3134087-B1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2020-03-18 | — | — | EP | disclosed |
| EP-3134087-B1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2020-03-18 | — | — | EP | disclosed |
| US-9688698-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688698-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688698-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2017-06-27 | — | — | US | disclosed |
| EP-3134087-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | Pfizer Inc. (US) | 2017-03-01 | — | — | EP | disclosed |
| CN-106232118-A | Heteroaromatic compounds and their use as dopamine D1 ligands | 辉瑞大药厂 | 2016-12-14 | — | — | CN | disclosed |
| WO-2015162515-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2015-10-29 | — | — | WO | disclosed |
| WO-2015162515-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2015-10-29 | — | — | WO | disclosed |
| US-20150307522-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2015-10-29 | — | — | US | disclosed |
| US-20150307522-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2015-10-29 | — | — | US | disclosed |
| US-20150307522-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2015-10-29 | — | — | US | disclosed |